Although our review found limited evidence for ICI efficacy in gynecologic SMARCA4-deficient tumors, favorable responses have been reported in specific subtypes such as small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT), which often harbor germline SMARCA4 mutations and exhibit an immune-inflamed phenotype. Here, SMARCA4 is linked to ovarian small cell carcinoma.